Welcome to the October ALTG newsletter – and my first…it’s a pleasure and an honour to be the group’s new President and I’m looking forward to working with my colleagues on the Management Advisory Committee, Scientific Advisory Committee and our members to continue to deliver the high quality research and education for which we are steadily becoming known. At our Members’ Meeting at this year’s Australian Lung Cancer Conference we formally acknowledged and thanked Paul Mitchell for his outstanding contribution as President over the last four years. Paul’s Presidency has seen the ALTG continue to grow and evolve, not only in terms of membership but, most importantly, in the development of the group’s portfolio of research activities and educational initiatives. Perhaps Paul’s “signature” contribution is his leadership of the ALTG as the driving force behind the establishment of TACT, the Thoracic Alliance for Cancer Trials. This international collaboration of thoracic oncology cooperative groups is almost unique among intergroup collaborations, with a genuinely global representation among its Board and Member Groups. For the ALTG to be leading this important initiative is a tremendous achievement.
As a cooperative trials group, devising and conducting high quality clinical trials and translating research outcomes into clinical practice is our core business. Through our international collaborations, ALTG-led trials and educational activities we are steadily developing a track record for excellence in investigator-led research in the Asia Pacific region. Just how far the group has come since its formation in 2004 is documented in our newly-released ALTG Research Report, 2004-2016. There is a tremendous “buzz” around the group at the moment and the last quarter of 2016 features a series of events that illustrates our energy and commitment to improving outcomes for our patients with lung cancer: the 2nd ALTG Preceptorship in Lung Cancer in Sydney on October 28-29; the inaugural ALTG Lung Cancer Symposium on November 12; a Members’ Meeting to focus on a strategic review and gap analysis of our research portfolio on November 11; and key study start-up activities for both NIVORAD and DREAM.
I look forward to seeing some of you at these events and working together over the coming months to continue to drive our growth and development.